US Code
Part E— General Provisions Relating to Drugs and Devices
§ 360bbb–8d. Notification, nondistribution, and recall of controlled substances

(a) Order to cease distribution and recall(1) In generalIf the Secretary determines there is a reasonable probability that a controlled substance would cause serious adverse health consequences or death, the Secretary may, after providing the appropriate person with an opportunity to consult with the agency, issue an order requiring manufacturers, importers, distributors, or pharmacists, who distribute such controlled substance to immediately cease distribution of such controlled substance.
(2) HearingAn order under paragraph (1) shall provide the person subject to the order with an opportunity for an informal hearing, to be held not later than 10 days after the date of issuance of the order, on whether adequate evidence exists to justify an amendment to the order, and what actions are required by such amended order pursuant to subparagraph (3).
(3) Order resolutionAfter an order is issued according to the process under paragraphs (1) and (2), the Secretary shall, except as provided in paragraph (4)—(A) vacate the order, if the Secretary determines that inadequate grounds exist to support the actions required by the order;
(B) continue the order ceasing distribution of the controlled substance until a date specified in such order; or
(C) amend the order to require a recall of the controlled substance, including any requirements to notify appropriate persons, a timetable for the recall to occur, and a schedule for updates to be provided to the Secretary regarding such recall.
(4) Risk assessmentIf the Secretary determines that the risk of recalling a controlled substance presents a greater health risk than the health risk of not recalling such controlled substance from use, an amended order under subparagraph (B) or (C) of paragraph (3) shall not include either a recall order for, or an order to cease distribution of, such controlled substance, as applicable.
(5) Action following orderAny person who is subject to an order pursuant to subparagraph (B) or (C) of paragraph (3) shall immediately cease distribution of or recall, as applicable, the controlled substance and provide notification as required by such order.
(b) Notice to persons affectedIf the Secretary determines necessary, the Secretary may require the person subject to an order pursuant to paragraph (1) or an amended order pursuant to subparagraph (B) or (C) of paragraph (3) to provide either a notice of a recall order for, or an order to cease distribution of, such controlled substance, as applicable, under this section to appropriate persons, including persons who manufacture, distribute, import, or offer for sale such product that is the subject of an order and to the public. In providing such notice, the Secretary may use the assistance of health professionals who prescribed or dispensed such controlled substances.
(c) NondelegationAn order described in subsection (a)(3) shall be ordered by the Secretary or an official designated by the Secretary. An official may not be so designated under this section unless the official is the Director of the Center for Drug Evaluation and Research or an official senior to such Director.
(d) Savings clauseNothing contained in this section shall be construed as limiting—(1) the authority of the Secretary to issue an order to cease distribution of, or to recall, any drug under any other provision of this chapter or the Public Health Service Act [42 U.S.C. 201 et seq.]; or
(2) the ability of the Secretary to request any person to perform a voluntary activity related to any drug subject to this chapter or the Public Health Service Act.

Structure US Code

US Code

Title 21— FOOD AND DRUGS

CHAPTER 9— FEDERAL FOOD, DRUG, AND COSMETIC ACT

SUBCHAPTER V— DRUGS AND DEVICES

Part E— General Provisions Relating to Drugs and Devices

§ 360bbb. Expanded access to unapproved therapies and diagnostics

§ 360bbb–0. Expanded access policy required for investigational drugs

§ 360bbb–0a. Investigational drugs for use by eligible patients

§ 360bbb–1. Dispute resolution

§ 360bbb–2. Classification of products

§ 360bbb–3. Authorization for medical products for use in emergencies

§ 360bbb–3a. Emergency use of medical products

§ 360bbb–3b. Products held for emergency use

§ 360bbb–3c. Expedited development and review of medical products for emergency uses

§ 360bbb–4. Countermeasure development, review, and technical assistance

§ 360bbb–4a. Priority review to encourage treatments for agents that present national security threats

§ 360bbb–4b. Medical countermeasure master files

§ 360bbb–5. Critical Path Public-Private Partnerships

§ 360bbb–5a. Emerging technology program

§ 360bbb–6. Risk communication

§ 360bbb–7. Notification

§ 360bbb–8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments

§ 360bbb–8a. Optimizing global clinical trials

§ 360bbb–8b. Use of clinical investigation data from outside the United States

§ 360bbb–8c. Patient participation in medical product discussion

§ 360bbb–8d. Notification, nondistribution, and recall of controlled substances